NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5562.50 62.00 (1.13%)

586.2K NSE+BSE Volume

High volume today

NSE 03 Jul, 2026 3:31 PM (IST)

66,508

Market Cap

High in industry

Beta 1Year

Very Low volatility

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Search Inside the pdf :

Alkem Laboratories Ltd.

29 May 2026

5562.50

1.13%

Alkem Labs (SELL): EBITDA Margin likely flat in FY27; valuations expensive

Sell: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT reported 4.8%/7.4%/-4.4% above our estimates. EBITDA Margin reported 36 bps above our estimates at 14.4%

Number of FII/FPI investors decreased from 613 to 607 in Mar 2026 qtr

Alkem Laboratories Ltd.

28 May 2026

5562.50

1.13%

Resilient growth in India; robust FY27 outlook

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem)’s Q4FY26 performance was decent. India branded grew 10% while reported growth of India business was lower at 8.9% due to restructuring of trade generics.

Alkem Laboratories Ltd. is trading at high day volume of 568.3K.

Alkem Laboratories Ltd.

28 May 2026

5562.50

1.13%

Strong finish; softer road ahead

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

Alkem Laboratories (ALKEM) delivered a better-than-expected financial performance with a 4%, 6%, and 16% beat on revenue, EBITDA, and PAT for 4QFY26.

Alkem Laboratories Ltd.'s price crossed above 200Day SMA today

Alkem Laboratories Ltd.

18 Feb 2026

5562.50

1.13%

Expanding scope of business in the Medtech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

Alkem Lab (ALKEM) is advancing its MedTech strategy through the acquisition of up to a 55% stake in Occlutech for ~EUR99m (~INR10.6b), gaining control of a specialist in minimally invasive devices for congenital heart disease, stroke prevention, and heart failure.

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

15 Feb 2026

5562.50

1.13%

Alkem Labs (HOLD): Ex - US international segment performing strongly

Hold: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT reported 1.3%/2.4% and -3.4% below our estimates. EBITDA margin reported 25bps lower than estimates at 22.2%

Alkem Laboratories Ltd. is trading at high day volume of 568.3K.

Alkem Laboratories Ltd.

15 Feb 2026

5562.50

1.13%

Temporary pause in India; new venture scale-up on cards

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) reported decent numbers in Q3FY26 led by its international operations. Domestic biz growth slowed to 5.6% YoY, hit by inventory stocking last year and deceleration in trade generics. Management is confident of posting double-digit growth in FY26 (9MFY26 growth at ~10%).

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

14 Feb 2026

5562.50

1.13%

Acquisition of Occlutech to open opportunities in Med-tech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM is taking significant steps in its Medtech journey through acquiring Occlutech (develops, manufactures, and commercialized medical devices for congenital heart disease, stroke prevention and heart failure).

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

14 Nov 2025

5562.50

1.13%

Alkem Labs (HOLD): Earnings Beat; increased EBITDA margin guidance

Hold: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 9%/9% and 2.8% above our estimates. EBITDA margin reported in line with our estimates at 23%

Number of FII/FPI investors decreased from 613 to 607 in Mar 2026 qtr

Alkem Laboratories Ltd.

14 Nov 2025

5562.50

1.13%

Traction across segments scaling margins to newer highs

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) delivered a strong Q2FY26 result led by traction across regions. Growth in India biz (+12% YoY) was led by better traction in chronic therapies and recent foray in medical devices segment, while new launches including gEntresto boosted US revenue (+28%).

Number of FII/FPI investors decreased from 613 to 607 in Mar 2026 qtr

Alkem Laboratories Ltd.

13 Nov 2025

5562.50

1.13%

Opex from CDMO/Med-tech to constrain margin expansion over the near term

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM Laboratories (ALKEM) delivered better-than-expected revenue/EBITDA/PAT, with a beat of 6%/9%/13% for the quarter. The superior performance was driven by broad-based higher revenue growth and lower-than-expected R&D spend for the quarter.

Number of FII/FPI investors decreased from 613 to 607 in Mar 2026 qtr

Is Alkem Laboratories Ltd. worth buying?

141 Votes:

Buy 79.43%

Sell 14.18%

Hold 6.38%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf